Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Receivables (2020 - 2023)

Relay Therapeutics (RLAY) has disclosed Receivables for 4 consecutive years, with $211000.0 as the latest value for Q3 2023.

  • Quarterly Receivables fell 95.88% to $211000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $211000.0 through Sep 2023, down 95.88% year-over-year, with the annual reading at $5.2 million for FY2022, 5.65% up from the prior year.
  • Receivables for Q3 2023 was $211000.0 at Relay Therapeutics, up from $78000.0 in the prior quarter.
  • The five-year high for Receivables was $82.7 million in Q4 2020, with the low at $78000.0 in Q2 2023.
  • Average Receivables over 4 years is $11.2 million, with a median of $5.1 million recorded in 2021.
  • The sharpest move saw Receivables grew 13.77% in 2022, then plummeted 98.47% in 2023.
  • Over 4 years, Receivables stood at $82.7 million in 2020, then tumbled by 94.02% to $4.9 million in 2021, then grew by 5.65% to $5.2 million in 2022, then plummeted by 95.96% to $211000.0 in 2023.
  • According to Business Quant data, Receivables over the past three periods came in at $211000.0, $78000.0, and $5.2 million for Q3 2023, Q2 2023, and Q1 2023 respectively.